Get the Stockscreener App
11.55
0.26%
0.03
Atara Biotherapeutics Inc stock is traded at $11.55, with a volume of 39,781.
It is up +0.26% in the last 24 hours and up +48.08% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
See More
Previous Close:
$11.52
Open:
$11.4
24h Volume:
39,781
Relative Volume:
0.66
Market Cap:
$68.85M
Revenue:
$100.44M
Net Income/Loss:
$-133.16M
P/E Ratio:
-0.4484
EPS:
-25.76
Net Cash Flow:
$-94.85M
1W Performance:
-0.26%
1M Performance:
+48.08%
6M Performance:
+30.07%
1Y Performance:
+11.06%
1-Day Range:
$10.92
$11.73
1-Week Range:
$10.69
$12.85
52-Week Range:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
11.55 | 68.68M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
What are the latest earnings results for Atara Biotherapeutics Inc.Post Market Growth Plan With High Returns - jammulinksnews.com
FDA Accepts Atara Biotherapeutics’ Resubmission of BLA for Tabelecleucel - CGTLive®
What are Atara Biotherapeutics Inc. company’s key revenue driversBeginner Investor Guidance For 2025 - jammulinksnews.com
Atara Biotherapeutics Plunges 16.09% Post Reverse Split - AInvest
Is it the right time to buy Atara Biotherapeutics Inc. stockDaily Trading Guidance To Watch Now - jammulinksnews.com
Atara Biotherapeutics Inc. Stock Lags Behind Sector BenchmarksHigh Accuracy Alerts for ROI Traders Detected - metal.it
Atara Biotherapeutics Inc. Recovery Potential Based on Technical ToolsValue Investing Picks With Stability Outlined - metal.it
Published on: 2025-07-29 09:26:28 - metal.it
Fibonacci Support Holding Strong in Atara Biotherapeutics Inc.Multi-Bagger Potential Stock Forecast Tools Released - metal.it
Published on: 2025-07-28 23:04:32 - metal.it
Is Atara Biotherapeutics Inc. a growth stock or a value stockRapid return acceleration - jammulinksnews.com
What makes Atara Biotherapeutics Inc. stock price move sharplyMaximize gains with proven stock analysis - jammulinksnews.com
What are analysts’ price targets for Atara Biotherapeutics Inc. in the next 12 monthsFree Investment Community - jammulinksnews.com
Should I hold or sell Atara Biotherapeutics Inc. stock in 2025Invest smarter with actionable stock recommendations - jammulinksnews.com
Intrinsic Value of Atara Biotherapeutics Inc. Stock: Is It Undervalued or Overvalued Portfolio Positioning Strategy With Timing - metal.it
What is Atara Biotherapeutics Inc. company’s growth strategyLow Risk Watchlist That Work - jammulinksnews.com
What is the dividend policy of Atara Biotherapeutics Inc. stockConsistently high yield - jammulinksnews.com
What are the technical indicators suggesting about Atara Biotherapeutics Inc.Build wealth faster with disciplined trading - jammulinksnews.com
What catalysts could drive Atara Biotherapeutics Inc. stock higher in 2025Free Expert Stock Watchlist - jammulinksnews.com
Why is Atara Biotherapeutics Inc. stock attracting strong analyst attentionUnlock high-yield investment opportunities - jammulinksnews.com
What is the risk reward ratio of investing in Atara Biotherapeutics Inc. stockHigh-yield portfolio picks - jammulinksnews.com
How Atara Biotherapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - Newser
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Rocket Pharmaceuticals (RCKT) and Atara Biotherapeutics (ATRA) - The Globe and Mail
What analysts say about Atara Biotherapeutics Inc. stockMarket-leading capital gains - Autocar Professional
What drives Atara Biotherapeutics Inc. stock priceExplosive capital appreciation - PrintWeekIndia
Atara Biotherapeutics stock jumps after FDA accepts BLA for tab-cel - Investing.com India
FDA accepts Atara’s BLA for tab-cel with priority review By Investing.com - Investing.com Nigeria
FDA accepts Atara’s BLA for tab-cel with priority review - Investing.com
Atara gets FDA priority review for Tabelecleucel application - Seeking Alpha
FDA Accepts Atara Biotherapeutics' BLA for Tabelecleucel (ATRA) | ATRA Stock News - GuruFocus
Atara Biotherapeutics stock jumps after FDA accepts BLA for tab-cel By Investing.com - Investing.com South Africa
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority - GuruFocus
FDA Accepts Atara Biotherapeutics' BLA for Tabelecleucel | ATRA Stock News - GuruFocus
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Business Wire
Innovation Ltd Panacea Buys 19,335 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock - Defense World
Atara Biotherapeutics Inc. Stock Analysis and ForecastHigh-profit trading signals - Autocar Professional
Atara gains after insider purchase - MSN
Is Atara Biotherapeutics Inc. a good long term investmentConsistent triple-digit returns - jammulinksnews.com
Atara Biotherapeutics (ATRA) Shares Surge After Insider Purchase - GuruFocus
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atara Biotherapeutics Inc Stock (ATRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
May 16 '25 |
Sale |
6.76 |
2,218 |
15,000 |
37,067 |
| Nguyen AnhCo | President and CEO |
May 16 '25 |
Sale |
6.76 |
3,276 |
22,156 |
70,847 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):